Artificial intelligence to improve ischemia prediction in Rubidium Positron Emission Tomography-a validation study.

"Declarations Competing interestsSimon M. Frey: nothing to declare.Adam Bakula: nothing to declare.Andrew Tsirkin: head modeling and development of Exploris Health.Vasily Vasilchenko: developer of MPA model at Exploris Health.Peter Ruff: CEO of Exploris Health, stock owner Exploris Health.Caroline Oehri: chief operating officer at Exploris Health, stock owner Exploris Health.Melissa F. Amrein: nothing to declare.Gabrielle Huré: nothing to declare.Klara Rumora: nothing to declare.Ibrahim Schäfer: nothing to declare.Federico Caobelli: nothing to declare.Philip Haaf: nothing to declare.Christian E. Mueller: no conflict of interest to declare regarding this project. Dr. Mueller has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the University Hospital Basel, the University of Basel, Abbott, Astra Zeneca, Beckman Coulter, Idorsia, Novartis, Ortho Diagnostics, Quidel, Roche, Siemens, Singulex, SpinChip and Sphingotec, as well as speaker honoraria/consulting honoraria from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Idorsia, Novartis, Osler, Roche, Sanofi and SpinChip.Bjoern Andrew Remppis: advisory board member Exploris Health.Hans-Peter Brunner-La Rocca: advisory board member Exploris Health, stock owner Exploris Health, unrestricted research grant by and advisor to Roche Diagnostics.Michael J. Zellweger: advisory board member Exploris Health, stock owner Exploris Health. Ethics approvalThe study was carried out according to the principles of the Declaration of Helsinki and was approved by the local ethics committee (Ethikkommission der Nordwest- und Zentralschweiz EKNZ (ethics committee of north western and central Switzerland, project ID: PB_2018-00076/EK 67/08). Consent to participateWritten informed consent was obtained from all participants. Consent for publicationNot applicable. Competing interests Simon M. Frey: nothing to declare. Adam Bakula: nothing to declare. Andrew Tsirkin: head modeling and development of Exploris Health. Vasily Vasilchenko: developer of MPA model at Exploris Health. Peter Ruff: CEO of Exploris Health, stock owner Exploris Health. Caroline Oehri: chief operating officer at Exploris Health, stock owner Exploris Health. Melissa F. Amrein: nothing to declare. Gabrielle Huré: nothing to declare. Klara Rumora: nothing to declare. Ibrahim Schäfer: nothing to declare. Federico Caobelli: nothing to declare. Philip Haaf: nothing to declare. Christian E. Mueller: no conflict of interest to declare regarding this project. Dr. Mueller has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the University Hospital Basel, the University of Basel, Abbott, Astra Zeneca, Beckman Coulter, Idorsia, Novartis, Ortho Diagnostics, Quidel, Roche, Siemens, Singulex, SpinChip and Sphingotec, as well as speaker honoraria/consulting honoraria from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Idorsia, Novartis, Osler, Roche, Sanofi and SpinChip. Bjoern Andrew Remppis: advisory board member Exploris Health. Hans-Peter Brunner-La Rocca: advisory board member Exploris Health, stock owner Exploris Health, unrestricted research grant by and advisor to Roche Diagnostics. Michael J. Zellweger: advisory board member Exploris Health, stock owner Exploris Health."

"Funding Open access funding provided by University of Basel Simon M. Frey received funding from the University Basel Research Fund (3MS1089). Laboratory tests were funded by a grant of the Basel Cardiology Foundation, Switzerland. Both foundations were not involved in study design, data interpretation or drafting of the manuscript."